Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Steinberg who wrote (897)	6/12/1998 5:20:00 AM
From: Tony van Werkhooven	Respond to of 1491

Zvi- thanks for the update. Is it fair to assume from your update that there should not be any further major dilution of the stock in the future? Thanks Tony

To: Zvi Steinberg who wrote (897)	6/12/1998 7:12:00 AM
From: Ariella	Respond to of 1491

Dear Zvi, Thanks a million for the update. Presumably you called company for info? The news about incoming payments from BOL exceeding cash burn is fantastic. Wonder what quarter we will be in when that happens -- Q2 of 1999? The timing is important. You write: << The current cash position of $5.5mm therefore should increase over time.>> Actually, won't the cash reserve be less, depending on when company rises above breakeven? All those tax loss carryforwards will come in handy next year, apparently . That these funds from Lotemax and Alrex are sufficient to fund smaller trials for tamoxifen and Le-T is also great. I can't imagine that we won't get a partner for HU-211 stroke Phase III trial. How about you? Regards, Ariella P.S. Maybe it's time we throw up a set of projections for 1999 on the boards.

To: Zvi Steinberg who wrote (897)	6/12/1998 9:03:00 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1491

Nice summary. The one element that was omitted, which slows the progress towards eliminating cash burn (since burn rate is not the level of expenditure, but the rate at which cash reserves are depleted by those expenditures)is the repayment of the BOL $5 million advance. Until that is repaid, Pharmos only receives 61% of what would have been forthcoming from BOL (the other 39% repaying the advance). NeuroInvestment (www.neuroinv.com)